Everything below concerns stoichiometric ratio. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H24N6O4 | Free tripeptide, without copper |
| Molecular weight | About 340 g/mol | Peptide portion only |
| Appearance | Blue to violet powder | Color from copper coordination |
| Solubility | Soluble in water | pH influences dissolution |
| Common synonyms | Copper tripeptide-1, Cu-GHK | Seen on ingredient labels |
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Current or previous treatment with anti-resorptive or anti-angiogenic therapy Expose bone or bone that can be probed through intra-oral or extra-oral fistula in the maxillofacial region that has persisted for longer than 8 weeks. No history of radiation therapy or metastatic disease to the jaw. Osteonecrosis, or localized death of bone tissue, of the jaws, is a rare potential complication in cancer patients receiving treatments including radiation, chemotherapy, or in patients with tumors or infectious embolic events. In 2003, reports surfaced of the increased risk of osteonecrosis in patients receiving these therapies concomitant with intravenous bisphosphonate. Matrix metalloproteinase-2 may be a candidate gene for bisphosphonate-associated osteonecrosis of the jaws, since it is the only gene known to be associated with both bone abnormalities and atrial fibrillation, another side effect of bisphosphonates. In response to the growing base of literature on this association, the United States Food and Drug Administration issued a broad drug class warning of this complication for all bisphosphonates in 2005.
NADH-ferredoxin oxidoreductase reduced nicotinamide adenine dinucleotide-ferredoxin NADH-ferredoxin reductase NADH flavodoxin oxidoreductase NADH2-ferredoxin oxidoreductase Other enzymes in the family include:
Following the Warsaw Pact summit in Moscow, the Soviet Union proceeded with a massive military build-up along Poland's border in December 1980, but during the summit Kania forcefully argued with Leonid Brezhnev and other allied communists leaders against the feasibility of an external military intervention, and no action was taken. The United States, under presidents Jimmy Carter and Ronald Reagan, repeatedly warned the Soviets about the consequences of a direct intervention, while discouraging an open insurrection in Poland and signaling to the Polish opposition that there would be no rescue by the NATO forces. In February 1981, Defense Minister General Wojciech Jaruzelski assumed the position of prime minister. The Solidarity social revolt had thus far been free of any major use of force, but in March 1981 in Bydgoszcz three activists were beaten up by the secret police. In a nationwide "warning strike" the 9.5-million-strong Solidarity union was supported by the population at large, but a general strike was called off by Wałęsa after the 30 March settlement with the government. Both Solidarity and the communist party were badly split and the Soviets were losing patience. Kania was re-elected at the Party Congress in July, but the collapse of the economy continued and so did the general disorder. At the first Solidarity National Congress in September–October 1981 in Gdańsk, Lech Wałęsa was elected national chairman of the union with 55% of the vote.
An even better isolation of veratridine from veratrine is achieved using high-performance liquid chromatography (HPLC); as commercially available veratridine may vary in purity, HPLC purification of veratrine is a preferred method for isolation of veratridine for biological studies.
== Diagnosis == The evaluation of a suspected myopathy combines clinical assessment with laboratory, electrophysiological, imaging, histological and genetic testing, since no single test is diagnostic for all forms.
Sources: en.wikipedia.org
Aden Colony (Arabic: مُسْتْعَمَرَةْ عَدَنْ, romanised: Musta'marat 'Adan) was a crown colony of the United Kingdom from 1937 to 1963 located in the southern part of modern-day Yemen. It consisted of the port city of Aden and also included the outlying islands of Kamaran, Perim and the Khuria Muria archipelago with a total area of 192 km2 (74 sq mi). Initially a key port for the British East India Company, it was annexed by the British in 1839 to secure maritime routes and prevent piracy in the Arabian Sea. Its strategic position at the entrance to the Red Sea made it a vital stopover for ships traveling between Europe, India, and the Far East, especially after the opening of the Suez Canal in 1869. Aden quickly became a major coaling station and transit hub for British shipping, and its significance to the British Empire grew throughout the 19th and early 20th centuries. Prior to 1937, Aden had been governed as part of British India (originally as the Aden Settlement subordinate to the Bombay Presidency, and then as a Chief Commissioner's province). On 1 April 1937, Aden was separated from British India to become a Crown colony under the Government of India Act 1935, consisting of the city of Aden and its surrounding areas. The colony experienced rapid development due to its thriving port, but it was also marked by growing civil unrest. Economic inequality, labour strikes, and the rise of Arab nationalism contributed to increasing tensions, which were intensified by the anti-colonial sentiment in the Middle East.
== Description == An annual to perennial plant with creeping or erect branched stems to about 40 cm in height. The stems are square in cross-section and can vary from hairless on some plants to densely hairy on others, with a green to sometimes red or purplish colour. The leaves, which grow in opposite pairs, are narrowly oval, 2–3 cm long x 1 cm wide, downy, sparsely toothed towards the tip, and taper into a short stalk. All parts of the plant are strongly scented when crushed but it does not have noticeable glands on its surface. The small (6 mm) flowers are densely packed in whorls at the nodes, widely separated, above pairs of leaf-like bracts. The calyx is a ribbed tube about 3 mm long, with five triangular teeth, the lower two being narrower and slightly longer than the upper three; it is hairy both on the inside and the outside. The corolla has four mauve lobes or "petals" and is hairy only on the outside. The flowers are bisexual and have four long stamens, two (or all four) of which project well beyond the corolla lobes. There is one long style which is forked to produce two stigmas, which also project from the flower. The fruits consist of a cluster of four brown, 1-seeded nutlets, each about 0.7 mm long.
Under the United States Federal Analogue Act, compounds which are analogues of and "substantially similar" to Schedule I and Schedule II controlled substances may themselves be treated as Schedule I controlled substances. Consequent to this law, such substances may be considered illegal to sell, purchase, or possess. However, the law applies only if the compounds are intended for human consumption. The Federal Analogue Act has been considered "void for vagueness" as the meaning of "substantially similar" is not precisely defined. In addition, the law only applies to compounds explicitly intended for human consumption. As a result, if compounds are not marketed this way, they can still be legally sold. This has resulted in such compounds being marketed as "research chemicals", "bath salts", "plant food", and "not for human consumption", even though they actually are intended for human use. Such flaws have limited the law and led to calls for reform.
== Further reading == "Clean Water Act Analytical Methods". EPA. 2022-07-27. "Hazardous Waste Test Methods / SW-846". EPA. 2022-06-15. Eaton, Andrew D.; Greenberg, Arnold E.; Rice, Eugene W.; Clesceri, Lenore S.; Franson, Mary Ann H., eds. (2005). Standard Methods For the Examination of Water and Wastewater (21 ed.). American Public Health Association. ISBN 978-0-87553-047-5. Also available on CD-ROM and online by subscription.
== Pharmacokinetics == Although Levonantradol has been extensively tested on animals including cats, rodents, and non-human primates. It has also been tested among cancer patient populations in clinical trials. Levonantradol is most commonly administered intramuscularly (I.M.), however it can also be administered orally. The dosage can range from 0.25 mg-3.0 mg every 2–4 hours, and the half-life is 1–2 hours. In order to administer Levonantradol intramuscularly, the drug must be dissolved in 5% ethanol, 5% emulphur, and 90% sterile saline. Synthetic cannabinoids like Levonantradol readily cross the blood–brain barrier because they are highly lipophilic and have low molecular weights. Levonantradol's bioavailability is variable due to the first pass metabolism.
Sources: en.wikipedia.org
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.
The peptide and its copper form have been detected in human plasma, saliva, and urine. Early reports describe levels that fall with age. The functional meaning of these pools is still debated.
Chromatographic separation gives peptide purity, often reported as a percentage. Copper content is checked by a separate elemental method. Moisture and counter-ions may be reported as well.
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.